Long-Term Renal and Cardiovascular Outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants by Baseline Estimated GFR

被引:61
|
作者
Rahman, Mahboob [1 ]
Ford, Charles E. [1 ]
Cutler, Jeffrey A. [1 ]
Davis, Barry R. [1 ]
Piller, Linda B. [1 ]
Whelton, Paul K. [1 ]
Wright, Jackson T., Jr. [1 ]
Barzilay, Joshua I. [1 ]
Brown, Clinton D. [1 ]
Colon, Pedro J., Sr. [1 ]
Fine, Lawrence J. [1 ]
Grimm, Richard H., Jr. [1 ]
Gupta, Alok K. [1 ]
Baimbridge, Charles [1 ]
Haywood, L. Julian [1 ]
Henriquez, Mario A. [1 ]
Ilamaythi, Ekambaram [1 ]
Oparil, Suzanne [1 ]
Preston, Richard [1 ]
机构
[1] Univ Texas Houston, Sch Publ Hlth, Houston, TX 77030 USA
关键词
CHRONIC KIDNEY-DISEASE; BLOOD-PRESSURE CONTROL; HYPERTENSIVE PATIENTS; PROGRESSION; ASSOCIATION; AMERICAN; DESIGN;
D O I
10.2215/CJN.07800811
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background and objectives CKD is common among older patients. This article assesses long-term renal and cardiovascular outcomes in older high-risk hypertensive patients, stratified by baseline estimated GFR (eGFR), and long-term outcome efficacy of 5-year first-step treatment with amlodipine or lisinopril, each compared with chlorthalidone. Design, setting, participants, & measurements This was a long-term post-trial follow-up of hypertensive participants (n=31,350), aged >= 55 years, randomized to receive chlorthalidone, amlodipine, or lisinopril for 4-8 years at 593 centers. Participants were stratified by baseline eGFR (ml/min per 1.73 m(2)) as follows: normal/increased (>= 90; n=8027), mild reduction (60-89; n=17,778), and moderate/severe reduction (<60; n=5545). Outcomes were cardiovascular mortality (primary outcome), total mortality, coronary heart disease, cardiovascular disease, stroke, heart failure, and ESRD. Results After an average 8.8-year follow-up, total mortality was significantly higher in participants with moderate/severe eGFR reduction compared with those with normal and mildly reduced eGFR (P<0.001). in participants with an eGFR <60, there was no significant difference in cardiovascular mortality between chlorthalidone and amlodipine (P=0.64), or chlorthalidone and lisinopril (P=0.56). Likewise, no significant differences were observed for total mortality, coronary heart disease, cardiovascular disease, stroke, or ESRD. Conclusions CKD is associated with significantly higher long-term risk of cardiovascular events and mortality in older hypertensive patients. By eGFR stratum, 5-year treatment with amlodipine or lisinopril was not superior to chlorthalidone in preventing cardiovascular events, mortality, or ESRD during 9-year follow-up. Because data on proteinuria were not available, these findings may not be extrapolated to proteinuric CKD. Clin J Am Soc Nephrol 7: 989-1002, 2012. doi: 10.2215/CJN.07800811
引用
收藏
页码:989 / 1002
页数:14
相关论文
共 50 条
  • [21] Blood pressure control in Hispanic participants in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT).
    Margolis, KL
    Piller, LB
    Lewis, CE
    Goff, DC
    Cushman, WC
    Wright, JT
    Colon, PJ
    Ford, CE
    CIRCULATION, 2001, 103 (09) : 1348 - 1348
  • [22] ASSOCIATION BETWEEN LOWER ESTIMATED GLOMERULAR FILTRATION RATE (GFR) AND INCIDENT CANCER: A REPORT FROM THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT)
    Chen, D.
    Pressel, S.
    Davis, B.
    Dobre, M.
    Muntner, P.
    Sarnak, M.
    Simpson, L.
    Whelton, P.
    Wright, J. T.
    Rahman, M.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 63 (05) : A38 - A38
  • [23] THE EFFECT OF RENAL FUNCTION ON INCIDENCE OF CONGESTIVE HEART FAILURE: THE ANTIHYPERTENSIVE AND LIPID-LOWERING TREATMENT TO PREVENT HEART ATTACK TRIAL (ALLHAT) STUDY
    Kholghi, Maedeh Khayyat
    Oparil, Suzanne
    Davis, Barry
    Tereshchenko, Larisa G.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 752 - 752
  • [24] Relationship of 1 year hypokalemia incidence to clinical outcomes in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Alderman, Michael
    Calhoun, David
    Cushman, William
    Davis, Barry
    Eckfeldt, John
    Einhorn, Paula
    Ford, Charles
    Franklin, Stanley
    Furberg, Curt
    Ong, Stephen
    Oparil, Suzanne
    Papademetriou, Vasilios
    Piller, Linda
    Probstfield, Jeffrey
    CIRCULATION, 2006, 114 (18) : 576 - 576
  • [25] Blood Pressure Control by Drug Group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Cushman, William C.
    Ford, Charles E.
    Einhorn, Paula T.
    Wright, Jackson T., Jr.
    Preston, Richard A.
    Davis, Barry R.
    Basile, Jan N.
    Whelton, Paul K.
    Weiss, Robert J.
    Bastien, Arnaud
    Courtney, Donald L.
    Hamilton, Bruce P.
    Kirchner, Kent
    Louis, Gail T.
    Retta, Tamrat M.
    Vidt, Donald G.
    JOURNAL OF CLINICAL HYPERTENSION, 2008, 10 (10): : 751 - 760
  • [26] Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT)
    Davis, BR
    Cutler, JA
    Gordon, DJ
    Furberg, CD
    Wright, JT
    Cushman, WC
    Grimm, RH
    LaRosa, J
    Whelton, PK
    Perry, HM
    Alderman, MH
    Ford, CE
    Oparil, S
    Francis, C
    Proschan, M
    Pressel, S
    Black, HR
    Hawkins, CM
    AMERICAN JOURNAL OF HYPERTENSION, 1996, 9 (04) : 342 - 360
  • [27] Cardiovascular outcomes in hypertensives with coronary artery disease randomized to amlodipine versus lisinopril in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Leenen, F
    Nwachuku, C
    Cushman, W
    Black, H
    Simpson, L
    Davis, B
    JOURNAL OF HYPERTENSION, 2005, 23 : S21 - S22
  • [28] Legacy Effects of Baseline Blood Pressure 'Treatment Naivety' on All-cause and Cardiovascular Mortality in the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Ho, Chau
    Bresliln, Monique
    Chowdhury, Enayet
    Doust, Jenny
    Reid, Christopher M.
    Davis, Barry R.
    Simpson, Lara M.
    Nelson, Mark R.
    CIRCULATION, 2019, 140
  • [29] Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome - Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Wright, Jackson T.
    Harris-Haywood, Sonja
    Pressel, Sara
    Barzilay, Joshua
    Bairnbridge, Charles
    Bareis, Charles J.
    Basile, Jan N.
    Black, Henry R.
    Dart, Richard
    Gupta, Alok K.
    Hamilton, Bruce P.
    Einhorn, Paula T.
    Haywood, L. Julian
    Jafri, Syed Z. A.
    Louis, Gail T.
    Whelton, Paul K.
    Scott, Cranford L.
    Sinnnons, Debra L.
    Stanford, Carol
    Davis, Barry R.
    ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (02) : 207 - 217
  • [30] Baseline Quality of Life and Risk of Stroke in the Antihypertensive and Lipid Lowering to Prevent Heart Attack (ALLHAT) Trial
    Shams, Tanzila
    Auchus, Alexander P.
    Oparil, Suzanne
    Wright, Clinton
    Wright, Jackson
    Furlan, Anthony J.
    Sila, Cathy A.
    Davis, Barry
    Pressel, Sara
    Yamal, Jose-Miguel
    Einhorn, Paula
    Cutler, Jeff
    Lerner, Alan J.
    STROKE, 2015, 46